CL2021001739A1 - Inhibidores de la proteína de activación de fibroblastos. - Google Patents
Inhibidores de la proteína de activación de fibroblastos.Info
- Publication number
- CL2021001739A1 CL2021001739A1 CL2021001739A CL2021001739A CL2021001739A1 CL 2021001739 A1 CL2021001739 A1 CL 2021001739A1 CL 2021001739 A CL2021001739 A CL 2021001739A CL 2021001739 A CL2021001739 A CL 2021001739A CL 2021001739 A1 CL2021001739 A1 CL 2021001739A1
- Authority
- CL
- Chile
- Prior art keywords
- protein inhibitors
- activation protein
- fibroblast activation
- fibroblast
- fap
- Prior art date
Links
- 210000002950 fibroblast Anatomy 0.000 title abstract 2
- 229940121649 protein inhibitor Drugs 0.000 title abstract 2
- 239000012268 protein inhibitor Substances 0.000 title abstract 2
- 230000004913 activation Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229910017464 nitrogen compound Inorganic materials 0.000 abstract 1
- 150000002830 nitrogen compounds Chemical class 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962788722P | 2019-01-04 | 2019-01-04 | |
| US201962863853P | 2019-06-19 | 2019-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021001739A1 true CL2021001739A1 (es) | 2022-01-21 |
Family
ID=71404153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021001739A CL2021001739A1 (es) | 2019-01-04 | 2021-06-29 | Inhibidores de la proteína de activación de fibroblastos. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200216417A1 (https=) |
| EP (1) | EP3906024A4 (https=) |
| JP (1) | JP2022516555A (https=) |
| KR (1) | KR20210113634A (https=) |
| CN (1) | CN114126597A (https=) |
| AU (1) | AU2020204714A1 (https=) |
| BR (1) | BR112021011861A2 (https=) |
| CA (1) | CA3124525A1 (https=) |
| CL (1) | CL2021001739A1 (https=) |
| IL (1) | IL284434A (https=) |
| MX (1) | MX2021007948A (https=) |
| SG (1) | SG11202106399XA (https=) |
| WO (1) | WO2020142742A1 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12415771B2 (en) | 2019-06-19 | 2025-09-16 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116474108A (zh) | 2016-12-14 | 2023-07-25 | 普渡研究基金会 | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 |
| US11780821B2 (en) | 2017-12-15 | 2023-10-10 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| WO2019126731A1 (en) | 2017-12-22 | 2019-06-27 | Petra Pharma Corporation | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| US11504364B2 (en) | 2018-12-21 | 2022-11-22 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| EP4096677A4 (en) * | 2020-01-31 | 2024-02-28 | Purdue Research Foundation | Fibroblast activation protein (fap) - targeted antifibrotic therapy |
| CN115819443B (zh) * | 2022-08-02 | 2025-03-21 | 中国科学院上海应用物理研究所 | 一种含烯基化合物及其应用 |
| WO2025159534A1 (ko) * | 2024-01-24 | 2025-07-31 | 서울대학교산학협력단 | 3-스티릴피리딘 구조 기반의 섬유아세포 활성화 단백질 표적 물질 |
| CN118978511A (zh) * | 2024-08-02 | 2024-11-19 | 江苏华益科技有限公司 | 一种靶向fap化合物及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7399869B2 (en) * | 2005-05-19 | 2008-07-15 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| CA2617715A1 (en) * | 2005-08-11 | 2007-02-15 | F. Hoffmann-La Roche Ag | Pharmaceutical composition comprising a dpp-iv inhibitor |
| WO2013107820A1 (en) * | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
| US11780821B2 (en) * | 2017-12-15 | 2023-10-10 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| US11504364B2 (en) * | 2018-12-21 | 2022-11-22 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
-
2020
- 2020-01-03 JP JP2021538976A patent/JP2022516555A/ja active Pending
- 2020-01-03 CN CN202080007971.2A patent/CN114126597A/zh active Pending
- 2020-01-03 SG SG11202106399XA patent/SG11202106399XA/en unknown
- 2020-01-03 MX MX2021007948A patent/MX2021007948A/es unknown
- 2020-01-03 WO PCT/US2020/012260 patent/WO2020142742A1/en not_active Ceased
- 2020-01-03 AU AU2020204714A patent/AU2020204714A1/en not_active Abandoned
- 2020-01-03 BR BR112021011861-6A patent/BR112021011861A2/pt not_active Application Discontinuation
- 2020-01-03 KR KR1020217024699A patent/KR20210113634A/ko not_active Ceased
- 2020-01-03 EP EP20735966.2A patent/EP3906024A4/en not_active Withdrawn
- 2020-01-03 US US16/734,214 patent/US20200216417A1/en not_active Abandoned
- 2020-01-03 CA CA3124525A patent/CA3124525A1/en active Pending
-
2021
- 2021-06-28 IL IL284434A patent/IL284434A/en unknown
- 2021-06-29 CL CL2021001739A patent/CL2021001739A1/es unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12415771B2 (en) | 2019-06-19 | 2025-09-16 | Nmd Pharma A/S | Compounds for the treatment of neuromuscular disorders |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114126597A (zh) | 2022-03-01 |
| WO2020142742A1 (en) | 2020-07-09 |
| IL284434A (en) | 2021-08-31 |
| CA3124525A1 (en) | 2020-07-09 |
| JP2022516555A (ja) | 2022-02-28 |
| MX2021007948A (es) | 2021-08-11 |
| EP3906024A1 (en) | 2021-11-10 |
| BR112021011861A2 (pt) | 2021-09-08 |
| EP3906024A4 (en) | 2022-10-26 |
| SG11202106399XA (en) | 2021-07-29 |
| US20200216417A1 (en) | 2020-07-09 |
| KR20210113634A (ko) | 2021-09-16 |
| AU2020204714A1 (en) | 2021-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021001739A1 (es) | Inhibidores de la proteína de activación de fibroblastos. | |
| CL2020002082A1 (es) | Inhibidores pd-1/pd-l1. | |
| CL2021000084A1 (es) | Inhibidores de pd-1/pd-l1 | |
| CL2020003257A1 (es) | Compuestos antagonistas de pcsk9. | |
| CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
| CO2022001210A2 (es) | Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes | |
| BR112022000503A2 (pt) | Compostos úteis para tratar infecções por vírus influenza | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| BR112018013995A2 (pt) | terapia de combinação de vírus oncolítico e inibidor de ponto de verificação | |
| CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| CL2012001422A1 (es) | Compuestos derivados de sulfonil benzamidas sustituidas, inductores de apoptosis con selectividad por bcl-2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
| CL2007002166A1 (es) | Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer. | |
| CO2020015923A2 (es) | Antagonista de gremlin-1 para la prevención y tratamiento del cáncer | |
| MX378806B (es) | Inhibidores de la arginasa y sus aplicaciones terapéuticas. | |
| CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
| CL2011002494A1 (es) | Compuestos derivados de 7-aza-di-espiro-[3.0.4.1]-decan-8-carboxamida; composición farmacéutica que los comprenden; y uso para el tratamiento de un trastorno asociado con el virus de la hepatitis c (hcv) y el virus de inmunodeficiencia humana (vih). | |
| UY37646A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| UY37742A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112022001329A2 (pt) | Anticorpo biespecífico anti-egfr/anti-4-1bb e uso do mesmo | |
| BR112022001336A8 (pt) | Anticorpo biespecífico anti-her2/anti-4-1bb e uso do mesmo | |
| CL2021002318A1 (es) | Métodos de tratamiento de amiloidosis al |